Skip to main content
Premium Trial:

Request an Annual Quote

PharmaSeq, Hybridon

Premium

PharmaSeq, of Monmouth Junction, NJ, has received US Patent Number 6,376,187, “Electronically-indexed solid-phase assay for biomolecules.” This patent covers methods and materials for detecting biomolecules using beads with attached microtransponders that have information relevant to the assay encoded in their memory elements. The patent also describes a device that encodes the information in the transponders and reads the information. A similar patent, Number 6,361,950, was issued March 23rd.

 

Hybridon of Cambridge, Mass., has received US Patent Number 6,383,752, “Pseudo-cyclic oligonucleobases.” This patent covers a new class of oligonucleotides, “pseudo-cyclic oligonucleotides” (PCOs), that contain two oligonucleotide segments attached through their 3’-3’ or 5’-5’ ends. One segment has some functionality, and another is complementary to the 3’ or 5’ end of the functional segment. This complementary aspect enables PCOs to form intramolecular pseudo-cyclic structures, and to be more stable than conventional oligonucleotides. A fluorophore and quencher molecule attached to the PCOs will fluoresce in the linear configuration and be quenched in the cyclic formation.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.